CD30 and the NPM-ALK fusion protein (p80) are differentially expressed between peripheral blood and bone marrow in primary small cell variant of anaplastic large cell lymphoma

Norihiro Awaya, Shigehisa Mori, Hitoshi Takeuchi, Shigeo Mori, Yasuo Sugano, Tamihiro Kamata, Tsutomu Takeuchi, Toru Abe

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

The t(2;5)(p23;q35) translocation results in the formation of a unique chimeric NPM-ALK protein (p80). Expression of this protein is considered to be one of the clinical features of anaplastic large cell lymphoma (ALCL). Recently recognized as one clinical subtype of ALCL, the small cell variant is prone to have a leukemic presentation. Although the small cell variant has been recognized as a subtype of ALCL, the clinical properties of this subtype, especially the immunophenotype of lymphoma cells in peripheral blood, have not yet been fully described. This report shows that neither CD30 nor p80 is detected by immunostaining in the predominant small cell malignant clone and also in large lymphoma cells in peripheral blood, while large cells and occasionally observed small cells in bone marrow were found to be positive for CD30 and p80. Our findings suggest that differential expression of CD30 and p80 between peripheral blood and bone marrow lymphoma cells is a property of the small cell variant of ALCL.

Original languageEnglish
Pages (from-to)200-204
Number of pages5
JournalAmerican Journal of Hematology
Volume69
Issue number3
DOIs
Publication statusPublished - 2002
Externally publishedYes

Fingerprint

Bone Marrow
Anaplastic Large-Cell Lymphoma
Lymphoma
Bone Marrow Cells
Clone Cells
p80(NPM-ALK) protein
protein p80
Anaplastic small cell lymphoma
Proteins

Keywords

  • Anaplastic large cell lymphoma
  • NPM-ALK fusion protein
  • Peripheral blood
  • Small cell variant

ASJC Scopus subject areas

  • Hematology

Cite this

CD30 and the NPM-ALK fusion protein (p80) are differentially expressed between peripheral blood and bone marrow in primary small cell variant of anaplastic large cell lymphoma. / Awaya, Norihiro; Mori, Shigehisa; Takeuchi, Hitoshi; Mori, Shigeo; Sugano, Yasuo; Kamata, Tamihiro; Takeuchi, Tsutomu; Abe, Toru.

In: American Journal of Hematology, Vol. 69, No. 3, 2002, p. 200-204.

Research output: Contribution to journalArticle

Awaya, Norihiro ; Mori, Shigehisa ; Takeuchi, Hitoshi ; Mori, Shigeo ; Sugano, Yasuo ; Kamata, Tamihiro ; Takeuchi, Tsutomu ; Abe, Toru. / CD30 and the NPM-ALK fusion protein (p80) are differentially expressed between peripheral blood and bone marrow in primary small cell variant of anaplastic large cell lymphoma. In: American Journal of Hematology. 2002 ; Vol. 69, No. 3. pp. 200-204.
@article{42c3ed18ad5d422e9c12048ae967355a,
title = "CD30 and the NPM-ALK fusion protein (p80) are differentially expressed between peripheral blood and bone marrow in primary small cell variant of anaplastic large cell lymphoma",
abstract = "The t(2;5)(p23;q35) translocation results in the formation of a unique chimeric NPM-ALK protein (p80). Expression of this protein is considered to be one of the clinical features of anaplastic large cell lymphoma (ALCL). Recently recognized as one clinical subtype of ALCL, the small cell variant is prone to have a leukemic presentation. Although the small cell variant has been recognized as a subtype of ALCL, the clinical properties of this subtype, especially the immunophenotype of lymphoma cells in peripheral blood, have not yet been fully described. This report shows that neither CD30 nor p80 is detected by immunostaining in the predominant small cell malignant clone and also in large lymphoma cells in peripheral blood, while large cells and occasionally observed small cells in bone marrow were found to be positive for CD30 and p80. Our findings suggest that differential expression of CD30 and p80 between peripheral blood and bone marrow lymphoma cells is a property of the small cell variant of ALCL.",
keywords = "Anaplastic large cell lymphoma, NPM-ALK fusion protein, Peripheral blood, Small cell variant",
author = "Norihiro Awaya and Shigehisa Mori and Hitoshi Takeuchi and Shigeo Mori and Yasuo Sugano and Tamihiro Kamata and Tsutomu Takeuchi and Toru Abe",
year = "2002",
doi = "10.1002/ajh.10059",
language = "English",
volume = "69",
pages = "200--204",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - CD30 and the NPM-ALK fusion protein (p80) are differentially expressed between peripheral blood and bone marrow in primary small cell variant of anaplastic large cell lymphoma

AU - Awaya, Norihiro

AU - Mori, Shigehisa

AU - Takeuchi, Hitoshi

AU - Mori, Shigeo

AU - Sugano, Yasuo

AU - Kamata, Tamihiro

AU - Takeuchi, Tsutomu

AU - Abe, Toru

PY - 2002

Y1 - 2002

N2 - The t(2;5)(p23;q35) translocation results in the formation of a unique chimeric NPM-ALK protein (p80). Expression of this protein is considered to be one of the clinical features of anaplastic large cell lymphoma (ALCL). Recently recognized as one clinical subtype of ALCL, the small cell variant is prone to have a leukemic presentation. Although the small cell variant has been recognized as a subtype of ALCL, the clinical properties of this subtype, especially the immunophenotype of lymphoma cells in peripheral blood, have not yet been fully described. This report shows that neither CD30 nor p80 is detected by immunostaining in the predominant small cell malignant clone and also in large lymphoma cells in peripheral blood, while large cells and occasionally observed small cells in bone marrow were found to be positive for CD30 and p80. Our findings suggest that differential expression of CD30 and p80 between peripheral blood and bone marrow lymphoma cells is a property of the small cell variant of ALCL.

AB - The t(2;5)(p23;q35) translocation results in the formation of a unique chimeric NPM-ALK protein (p80). Expression of this protein is considered to be one of the clinical features of anaplastic large cell lymphoma (ALCL). Recently recognized as one clinical subtype of ALCL, the small cell variant is prone to have a leukemic presentation. Although the small cell variant has been recognized as a subtype of ALCL, the clinical properties of this subtype, especially the immunophenotype of lymphoma cells in peripheral blood, have not yet been fully described. This report shows that neither CD30 nor p80 is detected by immunostaining in the predominant small cell malignant clone and also in large lymphoma cells in peripheral blood, while large cells and occasionally observed small cells in bone marrow were found to be positive for CD30 and p80. Our findings suggest that differential expression of CD30 and p80 between peripheral blood and bone marrow lymphoma cells is a property of the small cell variant of ALCL.

KW - Anaplastic large cell lymphoma

KW - NPM-ALK fusion protein

KW - Peripheral blood

KW - Small cell variant

UR - http://www.scopus.com/inward/record.url?scp=0036183425&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036183425&partnerID=8YFLogxK

U2 - 10.1002/ajh.10059

DO - 10.1002/ajh.10059

M3 - Article

VL - 69

SP - 200

EP - 204

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 3

ER -